Invention Title:

NUCLEAR REPROGRAMMING FACTOR AND INDUCED PLURIPOTENT STEM CELLS

Publication number:

US20260317385

Publication date:
Section:

Chemistry; metallurgy

Class:

C07K14/4702

Inventors:

Applicant:

Smart overview of the Invention

Field of Invention: The invention pertains to nuclear reprogramming factors that reprogram somatic cells to produce induced pluripotent stem (iPS) cells. It includes methods for generating and maintaining iPS cells, as well as their applications in screening, testing, and stem cell therapy. Additionally, it covers somatic cells derived from differentiated iPS cells.

Background: Embryonic stem (ES) cells have the ability to differentiate into any cell type, offering potential for treating diseases like Parkinson's and juvenile diabetes. However, ethical concerns and rejection issues limit their use. iPS cells, derived from a patient's own somatic cells, could overcome these challenges, providing a promising alternative without ethical or rejection issues.

Existing Techniques: Previous methods for nuclear reprogramming involved using eggs, embryos, or ES cells, which raised ethical concerns. Techniques such as nuclear transfer and cell fusion faced issues of rejection and technical unreliability. There is a need for methods to generate iPS cells without these drawbacks.

Invention Summary: The invention introduces methods to derive iPS cells from somatic cells without using eggs, embryos, or ES cells. It identifies nuclear reprogramming factors comprising specific gene products, including those from the Oct, Klf, Myc, and Sox families, which enable the reprogramming process.

Key Components: The nuclear reprogramming factor may include gene products like Oct3/4, Klf4, Sox2, and possibly Sall4. These components facilitate the conversion of somatic cells into pluripotent stem cells, offering a reliable and reproducible method to generate iPS cells for research and clinical applications.